Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 29, 2008
Optimisation of circulating biomarkers of cell death for routine clinical use
A Greystoke, J Cummings, T Ward, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
November 13, 2018
Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic Review
M S Iqbal, G Vashisht, R McMenemin, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
|
November 5, 2024
"Oh when's your treatment ending?" "Never!" The unmet needs of cancer patients treated with immunological, biological and precision therapies: A qualitative interview study
L Crowe, M C Brown, J Lecouturier, et al.
British Journal of Cancer
|
October 19, 2013
A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity
A Gibb, A Greystoke, M Ranson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 27, 2006
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours
A Greystoke, S Blagden, A L Thomas, et al.
Journal of Cancer Research and Clinical Oncology
|
September 13, 2023
Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders
S Rae, E Plummer, L Fitzgerald, et al.
British Journal of Cancer
|
January 20, 2011
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
A Greystoke, J P B O'Connor, K Linton, et al.
British Journal of Cancer
|
February 18, 2011
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
O A Khan, M Gore, P Lorigan, et al.
British Journal of Cancer
|
June 24, 2024
Social determinants of health inequalities in early phase clinical trials in Northern England
S Rae, S Shaya, E Taylor, et al.
ESMO Real World Data and Digital Oncology
|
April 20, 2026
Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise study
S Lay-Flurrie, A Greystoke, C Rault, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 29, 2008
Optimisation of circulating biomarkers of cell death for routine clinical use
A Greystoke, J Cummings, T Ward, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
November 13, 2018
Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic Review
M S Iqbal, G Vashisht, R McMenemin, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society
|
November 5, 2024
"Oh when's your treatment ending?" "Never!" The unmet needs of cancer patients treated with immunological, biological and precision therapies: A qualitative interview study
L Crowe, M C Brown, J Lecouturier, et al.
British Journal of Cancer
|
October 19, 2013
A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity
A Gibb, A Greystoke, M Ranson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 27, 2006
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours
A Greystoke, S Blagden, A L Thomas, et al.
Journal of Cancer Research and Clinical Oncology
|
September 13, 2023
Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders
S Rae, E Plummer, L Fitzgerald, et al.
British Journal of Cancer
|
January 20, 2011
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
A Greystoke, J P B O'Connor, K Linton, et al.
British Journal of Cancer
|
February 18, 2011
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
O A Khan, M Gore, P Lorigan, et al.
British Journal of Cancer
|
June 24, 2024
Social determinants of health inequalities in early phase clinical trials in Northern England
S Rae, S Shaya, E Taylor, et al.
ESMO Real World Data and Digital Oncology
|
April 20, 2026
Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise study
S Lay-Flurrie, A Greystoke, C Rault, et al.
Page
of 4